GENERATION OF CHIMERIC ANTIGEN RECEPTOR mRNA MOLECULES FOR EXPRESSION IN PRIMARY NK CELLS
AssigneeImmunityBio, Inc.
InventorFereshteh PARVIZ
Life of this patent
Estimating the term…
Abstract
The invention relates to novel chimeric antigen (CAR) mRNA molecules, the methods of generating the molecules and methods of treating cancer with the molecules.
Claims27
A chimeric antigen receptor (CAR) comprising:
- a T7 promoter, a spacer sequence, a signal peptide, an antigen binding domain, a hinge region, a transmembrane (TM) domain, and an intracellular domain;
- wherein the signal peptide comprises a cluster of differentiation 64 (CD64) and/or an IgG heavy chain variable gene (IgGHv) signal peptide;
- and
- wherein the antigen binding domain binds to an antigen selected from the group consisting of cluster of differentiation 19 (CD19), B-cell maturation antigen (BCMA), B7 homolog 4 (B7H4), SARS-CoV-2 spike, and cluster of differentiation 30 alpha (CD30α).
(canceled)
A modified primary Natural Kill (NK) cell modified with an RNA molecule comprising one or more nucleic acids of a T7 promoter, a spacer sequence, a signal peptide sequence portion, an antigen binding domain sequence portion, a hinge region sequence portion, a transmembrane (TM) domain sequence portion and an intracellular domain sequence portion;
- wherein the signal peptide sequence comprises a sequence encoding cluster of differentiation 64 (CD64) and/or an IgG heavy chain variable gene (IgGHv);
- wherein the antigen binding domain comprises a sequence encoding an antigen binding portion that binds to an antigen selected from the group consisting of cluster of differentiation 19 (CD19), B-cell maturation antigen (BCMA), B7 homolog 4 (B7H4), SARS-CoV-2 spike, and cluster of differentiation 30 alpha (CD30α);
- and
- wherein the nucleic acid sequences are operably linked to each other as a single polynucleotide.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.